Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Catalent Inc | CTLT | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
54.00 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 31.8001 - 60.20 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 54.00 | USD |
Catalent Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
9.76B | 180.74M | - | 4.26B | -256M | -1.42 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Catalent News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CTLT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 54.98 | 55.195 | 53.96 | 54.59 | 1,574,429 | -0.98 | -1.78% |
1 Month | 55.75 | 56.73 | 53.96 | 55.60 | 1,500,724 | -1.75 | -3.14% |
3 Months | 57.00 | 57.1999 | 53.96 | 56.09 | 1,700,789 | -3.00 | -5.26% |
6 Months | 39.77 | 60.20 | 36.7387 | 53.58 | 2,240,104 | 14.23 | 35.78% |
1 Year | 37.15 | 60.20 | 31.8001 | 47.56 | 2,510,918 | 16.85 | 45.36% |
3 Years | 104.97 | 142.64 | 31.45 | 62.99 | 2,072,933 | -50.97 | -48.56% |
5 Years | 44.70 | 142.64 | 31.04 | 66.93 | 1,683,454 | 9.30 | 20.81% |
Catalent Description
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents. |